Clinical Trials Logo

Digestive System Neoplasms clinical trials

View clinical trials related to Digestive System Neoplasms.

Filter by:

NCT ID: NCT05673434 Not yet recruiting - Digestive Tumor Clinical Trials

A Clinical Study on the Safety and Efficacy of CAR-T Therapy for the TM4SF1-positive Tumors of Digestive System

Start date: January 30, 2023
Phase: N/A
Study type: Interventional

Transmembrane 4 L Six Family Member 1 (TM4SF1) is highly expressed in many tumors of digestive system . The Chimeric Antigen Receptor T-cells (CAR-T) that target TM4SF1 has been generated in our good manufacturing practices (GMP) facility and the anti-tumor effects have been demonstrated in multiple in vitro and in vivo studies. Clinical studies are proposed here to evaluate the anti-tumor activity of these cell therapy products for treatment of patients with TM4SF1 positive tumors of digestive system. In this study, the safety, tolerance, and preliminary efficacy of CART-TM4SF1 cells will be examined in patients with refractory/recurrent advanced pancreatic cancer, colorectal cancer, gastric cancer or liver cancer. Clinical and immunological responses will be evaluated about 30 days and last up to 2 years after CAR-T cell infusion.

NCT ID: NCT05646043 Recruiting - Cancer, Rectum Clinical Trials

PREHAB - Improving Condition Before Surgery

Start date: December 1, 2022
Phase: N/A
Study type: Interventional

The pilot research project is focused on the feasibility of a prehabilitation program for two groups of diagnoses (esophageal and stomach cancer, rectal cancer).

NCT ID: NCT05639153 Recruiting - Clinical trials for Malignant Neoplasm of Digestive System

A Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DR30303 in Patients With Advanced Solid Tumors

Start date: May 13, 2022
Phase: Phase 1
Study type: Interventional

This study is an open-label Phase 1, First in Human trial of DR30303, a recombinant humanized monoclonal antibody that targets Claudin18.2 (CLDN18.2). It is composed of humanized variable domain of heavy chain of antibody (VHH) fused with engineered immunoglobulin gamma-1(IgG1) Fc. It is being testing against advanced and/or metastatic solid tumors.

NCT ID: NCT05636618 Recruiting - Clinical trials for Neuroendocrine Tumors

Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors

212-Pb-VMT
Start date: September 27, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study is Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors

NCT ID: NCT05624099 Recruiting - Clinical trials for Esophageal Neoplasms

Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.

Start date: August 1, 2023
Phase: Phase 2
Study type: Interventional

This is a prospective single-arm exploratory clinical study. The efficacy and safety of camrelizumab combined with chemoradiotherapy and camrelizumab combined with chemotherapy were evaluated in patients with advanced esophageal cancer who had not previously received any systemic antitumor therapy for esophageal cancer.

NCT ID: NCT05602935 Active, not recruiting - Neoplasms Clinical Trials

Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study

Start date: September 16, 2020
Phase: Phase 2
Study type: Interventional

This is a single-arm, phase II study of camrelizumab combined with SOX regimen in subjects with resectable locally advanced gastric cancer. The patients will receive camrelizumab ,S-1 and oxaliplatin given every 3 weeks for 3 cycles as neoadjuvant therapy. After the surgery, adjuvant therapy which includes camrelizumab and SOX regimen will begin.

NCT ID: NCT05583292 Completed - Clinical trials for Gastrointestinal Tumours

Mortality Predictions With Scorring Indices in Gastrointestinal Tumours

Start date: February 11, 2023
Phase:
Study type: Observational

The ASA-PS, SORT and Sarcopenia scores of the patients who will undergo surgery for a gastrointestinal tumor will be recorded. Thus, the correlation between preoperative indices and mortality/morbidity will be evaluated.

NCT ID: NCT05575986 Recruiting - Trombocitopenia Clinical Trials

Herombopag Olamine in the Treatment of Thrombocytopenia After Chemotherapy

hetrombopag
Start date: October 2022
Phase: Phase 4
Study type: Interventional

To evaluate the efficacy and safety of hetrombopag in the treatment of thrombocytopenia after chemotherapy in patients with digestive system malignant tumors

NCT ID: NCT05552729 Not yet recruiting - Clinical trials for Cognitive Impairment

Effects of Different Doses of Vitamin D on Cancer-related Cognitive Impairment in Patients With Gastrointestinal Tumors

Start date: September 22, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

To explore the effect of different doses of vitamin D drugs on gastrointestinal cancer cancer-related cognitive impairment, so as to provide reference and basis for the clinical use of our cognitive function surgery nursing plan for patients with gastrointestinal cancer.

NCT ID: NCT05551052 Active, not recruiting - Colorectal Cancer Clinical Trials

CRC Detection Reliable Assessment With Blood

CRC-DRAW
Start date: September 8, 2022
Phase:
Study type: Observational

The CRC DRAW study will assess the sensitivity and specificity of the blood-based, Next-Gen CRC Screening Test for the detection of CRC.